Usefulness of Medication Guidance Sheets for Patients with Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy.

Background/Aim: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAPtR). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients. Patients and Methods: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP +/- R. The prediction accuracy of the MGS was estimated before and after modification based on practical data. Results: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%. Conclusion: The accuracy of the original MGS for ESHAP +/- R was insufficient but greatly improved after the AEs duration modification.